Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I3 | Q14994 | 5/20 | 0.46 |
| ▸ | MMP8 | P22894 | 6/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102179 | 1.00 | NR1I3 (0.46) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL3093406 | 0.88 | MMP8 (0.45) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL3090378 | 0.88 | MMP8 (0.45) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL3090372 | 0.88 | MMP8 (0.45) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL27975122 | 0.85 | MMP8 (0.47) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL20809851 | 0.83 | CYP17A1 (0.43) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL7906077 | 0.83 | CA12 (0.45) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL3104630 | 0.82 | MMP8 (0.48) | NR1I3MMP8MMP3CA12CA1 | |
| SCHEMBL20809514 | 0.81 | MCHR1 (0.45) | NR1I3MMP8MMP3CYP17A1DRD2 | |
| SCHEMBL30476642 | 0.80 | NPC1 (0.53) | NR1I3CA12CA1CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803816-B2 | MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1934199-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039462-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070078165-A1 | MCH receptor antagonists | BERTHEL STEVEN J | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078165-A1 | MCH receptor antagonists | MCHR1, MCHR2, MC5R | NR1I3 274/4885MMP8 4816/4885MMP3 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.